Augurex Life Sciences Corp. news
Do you have a patient with Systemic Lupus Erythematosus (SLE) that you suspect may also have Sjögren’s Syndrome (SS)?
With shared clinical and serological features, overlapping SS with SLE is a comorbidity that is often challenging to identify to promptly assist clinical management. This may also lead to misdiagnoses of other connective tissue disorders.
New data on 14-3-3η (eta) enhances the detection rates of patients with seconda
Ms. Dakers began her career in Life Sciences at the University of British Columbia, managing technology transfer for the University Industry Liaison Office (UILO) where she was involved in the creation and spin-off of more than a dozen start-up high-tech and biotech companies. She then went on to co-found NeuroMed Technologies Inc., a private biotechnology company developing drugs for pain, anxiety, epilepsy, and cardiovascular disease where she raised $70M in venture funding. She
USPTO Awards Patent for Citrullinated 14-3-3: Expanding Augurex’s Portfolio in the Diagnosis of Rheumatoid Arthritis (RA)
On November 20th, 2018 the US Patent and Trademark Office (USPTO) awarded patent number 10,132,806 entitled “Antigens Derived From Citrullinated 14-3-3 And Uses Thereof In The Diagnosis of Rheumatoid Arthritis.” Citrullinated 14-3-3η auto-antibodies are express